gene expression analysis
Allarity Therapeutics Begins Phase I Trial of Dovitinib, Stenoparib Combo in Solid Tumors
The combination trial follows Allarity's decision to scrap development plans for dovitinib as a single agent in biomarker-selected kidney cancer patients.
A Wistar Institute team found that two hypomorphic p53 variants in separate domains of that gene generate a shared gene expression signature in certain African populations.
Based on growing evidence that the test provides information beyond other marketed breast cancer assays, the company is planning a commercial launch next year.
BeiGene Updates Phase III Data, Biomarker Analysis for Anti-PD-1 Drug in Nasopharyngeal Cancer
The analysis suggests tislelizumab plus chemo may be a first-line option for advanced patients, with a certain biomarker subgroup deriving the greatest benefit.
The Israeli firm's ENLIGHT test uses transcriptome sequencing plus functional drug interaction data to match more patients to drugs compared to current methods.